A randomised, phase 2 UK multi-centre study to determine reactogenicity of booster vaccination against ancestral and novel variants of SARS-CoV-2
Professor Krishna Chatterjee
Institution or company
Wellcome-MRC Institute of Metabolic Science, Cambridge
With the emergence of SARS-CoV-2 variants which may reduce vaccine efficacy against COVID-19, and with waning of immunity over time, it is likely that seasonal booster vaccines may be necessary for high risk groups. The COV-BOOST study aims to determine the safety and immune responses seen when people receive a COVID-19 booster vaccination, depending on whether they have received either the Oxford/AZ or Pfizer vaccines as their original course of 2 vaccines (known as prime-boost).
Participation: For this study, 2 participants from the COVID-19 BioResource aged >70 years who have received both doses of prime boost vaccination (Oxford/AZ or Pfizer) took part by providing a small blood sample. Appointments took place at the The NIHR Cambridge Clinical Research Facility.
Organisation: This study is organised by Professor Krishna Chaterjee from the Wellcome-MRC Institute of Metabolic Science.